Skip to main content

Table 2 IgM anti-PC autoantibody baseline distribution (median) according to characteristics of patients with rheumatoid arthritis

From: Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events

   IgM anti-PC, U/ml, baseline distribution
n Median p value
CV events during follow-up Non-CV 512 64.19 0.020
CV 141 51.79  
Age, years < 55 317 69.21 < 0.001
> 55 336 53.20  
Sex Female 443 64.81 < 0.001
Male 210 52.90  
BMI, kg/m2 < 25 334 67.28 0.002
25–30 235 55.02  
> 30 84 47.56  
Smoking Non-smoker 463 58.34 0.070
Current smoker 190 65.0  
Hypertension Non-hypertensive 554 62.68 0.013
Hypertensive 99 47.91  
Diabetes mellitus Non-diabetic 627 60.89 0.631
Diabetic 26 56.98  
Hyperlipidemia Non-hyperlipidemic 648 60.88 0.658
Hyperlipidemic 5 48.17  
Seropositive Seropositive 441 63.59 0.190
Seronegative 212 55.35  
DAS28 remission at 1 year Remission 237 61.11 0.895
Non-remission 416 60.10  
DAS28 remission at 2 years Remission 256 61.73 0.223
Non-remission 397 57.97  
  1. Statistical significance was tested with the Mann-Whitney U test
  2. BMI, body mass index; DAS28, Disease Activity Score 28-joint count; DAS28 remission, if DAS28 < 2.6; HAQ, Health Assessment Questionnaire; Anti-PC, phosphorylcholine antibodies